Improved prostate cancer imaging with SPECT/CT and MRI/MRSI

IEEE Nuclear Science Symposium Conference Record

Volumn 4, Issue , 2004, Pages 2402-2406

  Seo, Youngho ^a   Kurhanewicz, John ^a   Franc, Benjamin L ^a   Hawkins, Randall A ^a   Hasegawa, Bruce H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; ITERATIVE METHODS; MAGNETIC RESONANCE IMAGING; ONCOLOGY; PHOTONS;

ITERATIVE ALGORITHMS; LYMPH NODES; PROSTATE CANCER; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT);

MEDICAL IMAGING;

EID: 23844476215     PISSN: 10957863     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (26)

1. A. Jemal, R. C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E. J. Feuer, and M. J. Thun, "Cancer statistics, 2004," CA Cancer J. Clin., vol. 54, pp. 8-29, Jan.-Feb. 2004.
2. M. Han, A. W. Partin, S. Piantadosi, J. I. Epstein, and P. C. Walsh, "Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer," J. Urol., vol. 166, pp. 416-419, Aug. 2001.
3. S. A. Leibel, Z. Fuks, M. J. Zelefsky, M. Hunt, C. M. Burman, G. S. Mageras, C. S. Chui, A, Jackson, H. I. Amols, and C. C. Ling, "Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer," Semin. Oncol., vol. 30, pp. 596-615, Oct. 2003.
4. C. R. King, "LDR vs. HDR brachytherapy for localized prostate cancer: the view from radiobiological models," Brachytherapy, vol. 1, pp. 219-226, Dec. 2002.
5. D. Cho, C. J. Di Blasio, A. C. Rhee, and M. W. Kattan, "Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)," Urol. Oncol., vol. 21, pp. 282-291, Jul.-Aug. 2003.
6. J. H. Yoon, M. H. Chen, A. A. Renshaw, J. P. Richie, and A. V. D'Amico, "Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate cancer," Urology, vol. 60, pp. 454-457, Sep. 2002.
7. J. K. Burgers, G. H. Hinkle, and M. K. Haseman, "Monoclonal antibody imaging of recurrent and metastatic prostate cancer," Semin. Urol., vol. 13, pp. 103-112, May 1995.
8. J. Kotzerke, J. E. Gschwend, and B. Neumaier, "PET for prostate cancer imaging: still a quandary or the ultimate solution?," J. Nucl. Med., vol. 43, pp. 200-202, Feb. 2002.
9. D. B. Sodee, N. Malguria, P. Faulhaber, M. I. Resnick, J. Albert, and G. Bakale, "Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers," Urology, vol. 56, pp. 988-993, Dec. 2000.
10. J. Kurhanewicz, M. G. Swanson, S. J. Nelson, and D. B. Vigneron, "Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer," J. Magn. Reson. Imaging, vol. 16, pp. 451-463, Oct. 2002.
11. J. Lian, S. Hunjan, C. Dumoulin, J. Levin, R. Watkins, K. Rohling, R. Giaquinto, D. Kim, A. Lo, D. Spielman, B. Daniel, and L. Xing, "Integrating deformable MRI/MRSI and CT image registration into the prostate IMRT treatment planning," Int. J. Radiat. Oncol. Biol. Phys., vol. 57, pp. S207, Oct. 2003.
12. R. J. Ellis, D. B. Sodee, J. P. Spirnak, K. H. Dinchman, A. W. O'Leary, M. A. Samuels, M. I. Resniok, and T. J. Kinsella, "Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy," Int. J. Radiat. Oncol. Biol. Phys., vol. 48, pp. 683-7, Oct. 2000.
13. H. Jadvar, J. K. Pinski, and P. S. Conti, "FDG PET in suspected recurrent and metastatic prostate cancer," Oncol. Rep., vol. 10, pp. 1485-1488, Sep.-Oct. 2003.
14. M. Picchio, C. Messa, C. Landoni, L. Gianolli, S. Sironi, M. Brioschi, M. Matarrese, D. V. Matei, F. De Cobelli, A. Del Maschio, F. Rocco, P. Rigatti, and F. Fazio, "Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography," J. Urol., vol. 169, pp. 1337-1340, Apr. 2003.
15. T. Hara, N. Kosaka, and H. Kishi, "Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging," J. Nucl. Med., vol. 43, pp. 187-199, Feb. 2002.
16. S. S. Chang and W. D. W. Heston, "The clinical role of prostate-specific membrane antigen (PSMA)," Urol. Oncol., vol. 7, pp. 7-12, Jan.-Feb. 2002.
17. M. G. Swanson, D. B. Vigneron, T. K. Tran, and J. Kurhanewicz, "Magnetic resonance imaging and spectroscopic imaging of prostate cancer," Cancer Invest., vol. 19, pp. 510-523, May 2001.
18. T. J. Polascik, M. J. Manyak, M. K. Haseman, R. T. Gurganus, B. Rogers, R. T. Maguire, and A. W. Partin, "Comparison of clinical staging algorithms and 111 indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients," Cancer, vol. 85, pp. 1586-1592, Apr. 1999.
19. J. Star-Lack, S. J. Nelson, J. Kurhanewicz, L. R. Huang, and D. B. Vigneron, "Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING)," Magn. Reson. Med, vol. 38, pp. 311-321, Aug. 1997.
20. R. G. Males, D. B. Vigneron, J. Star-Lack, S. C. Falbo, S. J. Nelson, H. Hricak, and J. Kurhanewicz, "Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging," Magn. Reson. Med., vol. 43, pp. 17-22, Jan. 2000.
21. J. Kurhanewicz, D. B. Vigneron, H. Hricak, F. Parivar, S. J. Nelson, K. Shinohara, and P. R. Carroll, "Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectrosoopic imaging," Radiology, vol. 200, pp. 489-496, Aug. 1996.
22. J. Jung, F. Coakley, A. Qayyum, D. Vigneron, M. G. Swanson, V. Weinberg, K. Jones, P. Carroll, H. Hricak, and J. Kurhanewicz, "Endorectal MR spectroscopic imaging of the prostate: Investigation of a standardized evaluatoin system," Radiology, In press.
23. M. J. Manyak, G. H. Hinkle, J. O. Olsen, R. P. Chiaccherini, A. W. Partin, S. Piantadosi, J. K. Burgers, J. H. Texter, C. E. Neal, J. A. Libertino, G. L. Wright, Jr., and R. T. Maguire, "Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer," Urology, vol. 54, pp. 1058-1063, Dec. 1999.
24. S. Wilkinson and G. Chodak, "The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy," J. Urol., vol. 172, pp. 133-136, Jul. 2004.
25. C. T. Thomas, P. T. Bradshaw, B. H. Pollock, J. E. Montie, J. M. Taylor, H. D. Thames, P. W. McLaughlin, D. A. DeBiose, D. H. Hussey, and R. L. Wahl, "Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy," J. Clin. Oncol., vol. 21, pp. 1715-1721, May 2003.
26. C. J. Schettino, E. L. Kramer, M. E. Noz, S. Taneja, P. Padmanabhan, and H. Lepor, "Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer," AJR Am. J. Roentgenol., vol. 183, pp. 519-524, Aug. 2004.